ATE422368T1 - Multikomponenten impfstoffe gegen staphylococcus aureus - Google Patents

Multikomponenten impfstoffe gegen staphylococcus aureus

Info

Publication number
ATE422368T1
ATE422368T1 AT99942533T AT99942533T ATE422368T1 AT E422368 T1 ATE422368 T1 AT E422368T1 AT 99942533 T AT99942533 T AT 99942533T AT 99942533 T AT99942533 T AT 99942533T AT E422368 T1 ATE422368 T1 AT E422368T1
Authority
AT
Austria
Prior art keywords
proteins
fragments
fragment
protein
bacterial
Prior art date
Application number
AT99942533T
Other languages
English (en)
Inventor
Joseph Patti
Timothy J Foster
Magnus Hook
Original Assignee
Inhibitex Inc
Texas A & M Univ Sys
Trinity College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibitex Inc, Texas A & M Univ Sys, Trinity College Dublin filed Critical Inhibitex Inc
Application granted granted Critical
Publication of ATE422368T1 publication Critical patent/ATE422368T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99942533T 1998-08-31 1999-08-31 Multikomponenten impfstoffe gegen staphylococcus aureus ATE422368T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9843998P 1998-08-31 1998-08-31

Publications (1)

Publication Number Publication Date
ATE422368T1 true ATE422368T1 (de) 2009-02-15

Family

ID=22269290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942533T ATE422368T1 (de) 1998-08-31 1999-08-31 Multikomponenten impfstoffe gegen staphylococcus aureus

Country Status (13)

Country Link
EP (1) EP1109577B1 (de)
JP (2) JP2002523473A (de)
KR (1) KR100644953B1 (de)
CN (1) CN1314450C (de)
AT (1) ATE422368T1 (de)
AU (1) AU771426B2 (de)
BR (1) BR9913340A (de)
CA (2) CA2777661C (de)
DE (1) DE69940404D1 (de)
ES (1) ES2322409T3 (de)
IL (1) IL141639A (de)
MX (1) MXPA01002119A (de)
WO (1) WO2000012131A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4714342B2 (ja) * 1998-08-31 2011-06-29 ザ プラヴアスト フエロウス アンド スカラース オブ ザ カレツヂ オブ ザ ハリー アンド アンデイヴアイデツド トリニテイ オブ クイーン エリザベス ニヤー ダブリン コアグラーゼ陰性スタフィロコカス菌に由来のポリペプチド及びポリヌクレオチド
EP1121149A4 (de) * 1998-08-31 2002-03-20 Inhibitex Inc Immunotherapeutika gegen staphylokokkus mittels donor selektion und donor stimulation
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
WO2002034788A1 (en) * 2000-10-20 2002-05-02 Inhibitex, Inc. Monoclonal antibodies to the map protein and method of use in treating or preventing infections
EP1481011A4 (de) * 2002-03-05 2007-05-30 Inhibitex Inc Monoklonale und polyklonale antikörper, die koagulasenegative staphylokokkenproteine erkennen
CA2517439C (en) * 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
EP1613642A4 (de) * 2003-04-16 2008-07-02 Texas A & M Univ Sys Efb-protein von staphylococcus aureus und c3-bindestelle, die die komplementaktivierung inhibiert
US20070026011A1 (en) * 2003-05-29 2007-02-01 Inhibitex, Inc. Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
WO2006070776A1 (ja) * 2004-12-28 2006-07-06 Daiichi Pure Chemicals Co., Ltd. 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
AU2007281934B2 (en) * 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
EP2476433A1 (de) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogene Zusammensetzung
BRPI0721892A2 (pt) * 2007-07-23 2014-05-13 Vaccine Res Internat Plc Composição de vacina, inalador, célula, métodos para vacinar um animal contra uma infecção bacteriana, para preparar uma linhagem de célula de hibridoma, e para preparar uma vacina para um patógeno bacteriano, usos de uma composição, de soros humanos, e de um anticorpo humano, linhagem de célula de hibridoma, anticorpo, fragmento de ligação ativo, soro, processo para a produção de uma vacina, e, cultura de célula bacteriana
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
JP6192294B2 (ja) 2009-07-15 2017-09-06 エーアイエムエム セラピューティクス ベー．フェー． グラム陽性菌特異的結合化合物
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2654784B1 (de) * 2010-12-22 2016-12-07 Wyeth LLC Stabile immunogene zusammensetzungen aus staphylococcus aureus-antigenen
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2013168965A2 (ko) * 2012-05-07 2013-11-14 목암생명공학연구소 포도상구균 감염 예방용 백신 조성물
BR112015018014A2 (pt) 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
AU2015359503B2 (en) * 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
CN107007832A (zh) * 2016-01-28 2017-08-04 中创云牧科技咨询(北京)股份有限公司 一种ClfA-A靶位的金黄色葡萄球菌奶牛乳房炎疫苗的制备方法
JP7362667B2 (ja) 2018-02-12 2023-10-17 イニミューン・コーポレーション Ｔｏｌｌ様受容体リガンド
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) * 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US5189015A (en) * 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US5440014A (en) * 1990-08-10 1995-08-08 H+E,Uml/Oo/ K; Magnus Fibronectin binding peptide
US5851794A (en) * 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
DE69734601T2 (de) * 1996-05-16 2006-08-03 The Texas A & M University System, College Station Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen
SE9602496D0 (sv) * 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
CA2277793A1 (en) * 1997-01-21 1998-07-23 The Texas A & M University System Fibronectin binding protein compositions and methods of use
EP1034277B1 (de) * 1997-11-26 2012-06-27 Inhibitex, Inc. Extrazelluläre Matrix-bindende Proteine von Staphylococcus aureus

Also Published As

Publication number Publication date
ES2322409T3 (es) 2009-06-19
CA2777661C (en) 2014-10-21
JP2011168607A (ja) 2011-09-01
EP1109577A1 (de) 2001-06-27
CA2340304A1 (en) 2000-03-09
KR20010085745A (ko) 2001-09-07
JP2002523473A (ja) 2002-07-30
AU771426B2 (en) 2004-03-18
WO2000012131A1 (en) 2000-03-09
EP1109577A4 (de) 2002-03-13
CN1314450C (zh) 2007-05-09
MXPA01002119A (es) 2003-03-27
CN1317976A (zh) 2001-10-17
DE69940404D1 (de) 2009-03-26
EP1109577B1 (de) 2009-02-11
BR9913340A (pt) 2001-11-06
AU5588999A (en) 2000-03-21
JP5460642B2 (ja) 2014-04-02
IL141639A (en) 2005-12-18
CA2340304C (en) 2012-12-04
IL141639A0 (en) 2002-03-10
KR100644953B1 (ko) 2006-11-10
CA2777661A1 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
ATE422368T1 (de) Multikomponenten impfstoffe gegen staphylococcus aureus
WO2002072600A3 (en) Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
WO1999027109A3 (en) EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS)
AU3126097A (en) Collagen binding protein compositions and methods of use
DK0759774T3 (da) Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
AU2002305450A1 (en) Proteomimetic compounds and methods
DE60218998D1 (de) Auf Bläschen basierendes Impfstoff gegen Chlamydia
WO2001052791A3 (en) Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
AU5751000A (en) Groups of borrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
CY1112014T1 (el) Συνθεσεις αντιβακτηριακων εμβολιων
AR016295A1 (es) Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme
EP1988099A3 (de) Insektizide Proteine von Bacillus thuringiensis
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
ATE305791T1 (de) Pharmazeutische zubereitungen zur behandlung von magengeschwüren
WO1999001473A3 (en) Anti-bacterial methods and materials
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
ATE266091T1 (de) Rekombinante phagen
PT946730E (pt) Mutantes de toxina estreptococica c e metodos de utilizacao
GB9723945D0 (en) Tissue cement
CY1107038T1 (el) Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης
WO2002057281A3 (en) Aminoglycosides as antibiotics
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
AU2002224437A1 (en) Monoclonal antibodies to the map protein and method of use in treating or preventing infections
WO2005010167A3 (en) Antibodies to the fbsa protein of streptococcus agalactiae and their use in treating or preventing infections

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties